GlassScriptPhysician profile
Stacy J Gajewski
NPI 1467553404
$5,054.69
in general payments reported to CMS, 2019-2025
48 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $169 · 2021: $15.03 · 2022: $640 · 2023: $1,047 · 2024: $1,094 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.92 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $399.24 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $364.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $320.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $229.75 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $219.93 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $192.80 | 2019-2025 | Veozah |
| Dexcom, INC. | $189.56 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $178.88 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $140.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $128.20 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.52 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $112.63 | 2023-2025 | Injectafer |
| Abbott Laboratories | $112.61 | 2023-2025 | Freestyle Libre 3, Proclaim |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Gajewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.